Imugene Limited (IMU) Fair Value & Analysis
Healthcare · AU · Market cap A$39.1M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 4 days ago
Fair value updated Jun 26, 2026 — revised from A$0.4800 to A$0.0999 (−79.2%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range A$0.0791 – A$0.4139 · fair‑value band A$0.0582 – A$0.1325 · the A$0.1000 price screens above the A$0.0999 fair value. As of Jun 26, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Imugene Limited (IMU) currently trades at A$0.1000, while our model-based Fair Value estimate is A$0.0999 — implying the stock looks roughly 0.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$3.9M. Revenue declined 36.0% year over year. The balance sheet holds a net cash position of A$11.3M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Imugene Limited reported revenue of A$4.4M in FY2025 versus A$7.2M in FY2021, a compound −11.7%/yr. Reported net income was −A$69.0M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Imugene Limited (IMU) undervalued?
What is the fair value of IMU?
What is the quality score of IMU?
What is the revenue of Imugene Limited (IMU)?
What is the net profit margin of IMU?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.